Compare Dyne Therapeutics Inc. Common Stock (DYN) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs First Trust Cloud Computing ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while First Trust Cloud Computing ETF trades at $163.94 (market cap $3.57B). The key difference: First Trust Cloud Computing ETF is the larger of the two by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and First Trust Cloud Computing ETF for 84 Days on average.
| DYN | SKYY | |
|---|---|---|
Market Cap | $2.86B | $3.57B |
Volume | 3,341,579 | 236,993 |
Sector | Health | — |
52-Week High | $26.78 | $174.89 |
52-Week Low | $14.60 | $104.16 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SKYY, the First Trust Cloud Computing ETF, trades at $171.52, down 0.57% today but near its 52-week high. Technical indicators show a bullish trend with strong moving average support, though RSI suggests mild overbought conditions. The ETF provides diversified exposure to the cloud computing sector, benefiting from AI adoption and digital transformation trends. Recent news highlights institutional adjustments and positive coverage on cloud infrastructure growth.
The outlook for SKYY is positive, driven by secular trends in cloud computing and AI. Investment opportunities include sector growth and diversification benefits, while risks involve market volatility and sector-specific competition. The ETF's performance hinges on continued tech infrastructure spending and macroeconomic conditions affecting tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
